What changed for HIV and AIDS
A plain English summary of what recently moved in the public data Voxsanity tracks for HIV and AIDS. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 308 to 321 (+13)
- Late-stage (Phase 3) trials 15 to 16 (+1)
- Trials on record 5,001 to 5,152 (+151)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for HIV and AIDS in July 2026. Voxsanity tracks 29 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 207 trials tracked for HIV and AIDS that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05057858 · results posted 15 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 72 women across four groups of 18 each. Three groups were non-pregnant women randomly assigned to take a HIV prevention pill (known as oral PrEP, containing two medicines called tenofovir and emtricitabine) either 2, 4, or 7 times per week over eight weeks — representing poor, moderate, or perfect adherence to the dosing schedule. The fourth group consisted of pregnant women who also took the medication. The trial was measuring how much of the active drug ingredients built up in participants' blood at different dosing...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06307028 · results posted 28 April 2026
According to the results reported on ClinicalTrials.gov, this trial involved 23 participants, all of whom were Black women considered potentially eligible for PrEP (a medication taken to reduce the chances of getting HIV). The trial was testing a programme called SISTA-P, and its main focus was not on whether the programme prevented HIV, but rather on whether the programme itself was practical to run, acceptable to participants, and felt appropriate for the group it was designed for. Of the 23 people who started, 22 completed the study and 1 did not. The reported data shows that participants...
-
NCT03670316 · results posted 15 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03670316) enrolled 371 people who smoked — 185 in a group receiving an "Algorithm Treatment" (AT), which appears to be a structured, computer-guided approach to quitting smoking, and 186 in a group receiving "Enhanced Treatment as Usual" (eTAU), a more standard care approach. The trial measured whether people had stopped smoking in the seven days before their follow-up check, as well as several other related measures such as how many cigarettes people smoked per day, whether they tried to go without smoking for at least 24...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06582966 · results posted 13 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 participants in a single study group called "DoxyDOT Single Arm." The trial was looking at a dosing approach called doxyPEP — a form of the antibiotic doxycycline taken after potential exposure to certain sexually transmitted infections — given under direct observation (meaning a health worker watched participants take each dose). The study tracked how consistently participants took their weekly doses over the course of the trial, and also collected surveys about how acceptable the approach was to participants. Of...
-
NCT01818791 · results posted 11 March 2026
According to the results reported on ClinicalTrials.gov, this trial involved 909 young people across two groups. One group of 433 participants received a programme called "Making Proud Choices" on its own, while the other group of 476 participants received "Making Proud Choices" combined with an additional support framework called "Getting To Outcomes." The trial was measuring attitudes about abstinence, as well as staff capacity and how closely the programmes were delivered as intended. Of those who started, 275 in the first group and 305 in the second group completed the study. The reported...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06503991 · results posted 2 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06503991) enrolled 100 adults who took part in a program called the COACH Intervention, which involved community health worker (CHW) counselling sessions, doctor's visits, and phone calls over six months. The study was designed to look at how practical and workable (feasible) this program was, and to gather information on blood pressure control, medication habits, and knowledge about high blood pressure. Of the 100 people who started, 96 completed the study and 4 did not. The reported data shows that across all 100 partic...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06029712 · results posted 31 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 35 people in total — 17 in one group and 18 in the other. It was a crossover study, meaning everyone tried both approaches at different times: taking heart failure medicines as separate individual tablets, and taking them combined into a single "polypill." The trial was measuring whether people were more likely to take their medicines consistently with one format compared to the other, using pill counts and questionnaires. The reported data shows that when medicines were taken as a polypill, the overall pill-count ad...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02591420 · results posted 17 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 24 people in total — 8 in each of three groups. All three groups had recently acquired HIV. One group received immediate antiretroviral treatment (ART, the standard HIV medication) plus a dummy (placebo) infusion; a second group received immediate ART plus infusions of an antibody called VRC01; and a third group received VRC01 infusions first, with ART starting a short time later. The trial was measuring things like changes in the amount of HIV in the blood, how long it took for the virus to reach very low levels, and...
-
NCT06487390 · results posted 9 December 2025
According to the results reported on ClinicalTrials.gov, this pilot trial (NCT06487390) enrolled 46 healthcare providers who took part in a programme called "PrEP Pro" — a training intervention designed to support providers in offering HIV prevention medication (PrEP) and related sexual health care. Of the 46 who started, 32 completed the study, and 14 did not finish. The trial was primarily measuring whether the programme was practical to run (feasibility) and whether participants found it acceptable, using simple rating scales scored from 1 to 5. The reported data shows that on the feasibil...
-
NCT05540652 · results posted 19 November 2025
According to the results reported on ClinicalTrials.gov, this trial tested a program called Mindfulness-Based Queer Resilience (MBQR), an online mindfulness program designed for queer (LGBTQ+) people. The main goal was not to test whether the program "worked" in a medical sense, but rather to find out whether it was *feasible* (that is, could it be run practically — could researchers recruit and keep participants?) and *acceptable* (did participants find it satisfactory?). A total of 19 people enrolled in the program. The reported data shows that 19 participants started the program and 18 com...
-
NCT02990858 · results posted 12 November 2025
According to the results reported on ClinicalTrials.gov, this trial involved 43 people living with HIV who received a treatment called PRO 140, given as an injection under the skin. The trial was measuring how the treatment affected the amount of HIV in participants' blood (called "viral load"), as well as a type of immune cell called CD4 cells, which are important in HIV. Of the 43 people who started, 23 completed the trial and 20 did not finish. The reported data shows that, on average, participants' HIV viral load changed by 0.13 log10 copies/mL over the course of the treatment period (thi...
-
NCT06039579 · results posted 30 September 2025
According to the results reported on ClinicalTrials.gov, this trial tested two experimental treatments — called VH4004280 and VH4011499 — in people living with HIV-1 who were not on other HIV medicines at the time. The trial enrolled 44 participants in total, split across several small groups that received one of two dose levels of either treatment, a pre-specified dose of either treatment, or a dummy treatment (placebo). The main thing the trial set out to measure was how much the level of HIV in participants' blood (measured as "HIV-1 RNA," the genetic material of the virus) changed after up...
-
NCT05938621 · results posted 22 September 2025
According to the results reported on ClinicalTrials.gov, this trial involved four groups of healthcare providers, with 25 participants assigned to each group (100 in total). The four groups were: a "standard of care" group (no special programme), a "resilience intervention" group, a "resilience and stigma" group, and an "anti-stigma" group. The trial was measuring whether these different programmes were associated with changes in burnout levels among healthcare workers over a six-month period. Each group's participants were also responsible for caring for varying numbers of patients during the...
-
NCT06229132 · results posted 16 September 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 25 transgender and gender-diverse individuals, with 22 completing the study and 3 not finishing. The trial was measuring changes in several areas of mental wellbeing, including depression, anxiety, psychological distress, thoughts of suicide, alcohol use, and fear of future rejection based on gender identity. Each of these areas was tracked using a questionnaire with a numbered scale, with participants completing the measures at two points — the results data shows two scores for each measure, which appear to represent...
-
NCT05627258 · results posted 22 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05627258) enrolled 23 participants in total, spread across six groups of between 3 and 5 people each. The trial was measuring how participants responded in the short term after receiving a study product — specifically, it tracked any physical reactions near the site where the product was given (called "local" reactions), any whole-body reactions (called "systemic" reactions), and a range of other health and safety markers, including blood test results, new ongoing medical conditions, and serious medical events. These measu...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01234116 · results posted 15 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 16 people in total — 8 in a group receiving a medication called Kaletra, and 8 in a group receiving a medication called Raltegravir. Both medications were being used as post-exposure prophylaxis (PEP) — that is, treatment given after a potential exposure to HIV to try to prevent infection. The trial was measuring two main things: signs of unwanted side effects (such as nausea, vomiting, diarrhoea, and changes in liver test results), and whether any participants went on to acquire HIV during the study. Not everyone fin...
-
NCT05630885 · results posted 16 July 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 110 people in total — 74 in the group receiving a medicine called CVC (Cenicriviroc) and 36 in the placebo group (a dummy treatment with no active ingredient). The trial was measuring changes in arterial wall inflammation — specifically, how much a specialised type of scan called an 18-FDG-PET scan picked up signs of inflammation in the walls of major blood vessels (the aorta and carotid arteries) after 24 weeks. The scan produces a score called a Target-to-Background Ratio (TBR), which compares the activity in the ve...
-
NCT03587857 · results posted 1 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03587857) involved a single group of participants who used a mobile app called WYZ. The trial was a feasibility study — meaning it was designed to test whether running a full-scale study would be practical — rather than to prove whether the app does or does not work. The main things being measured were how many people signed up, how often they used the app, and how they engaged with its features, including medication tracking and a peer chat function. A total of 79 people started the study, and 69 completed it over the six...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01351389 · results posted 19 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 372 people across two groups — 184 received a "Brief Motivational Intervention" (BMI), which is a structured conversation designed to encourage reflection on behaviour, and 188 received "Brief Advice," a shorter, more straightforward form of guidance. The trial was measuring two main things: how much alcohol participants drank, and how many days they engaged in condomless sex (sex without a condom) in the past month. By the end of the study, 154 people in the BMI group and 173 in the Brief Advice group had completed t...
-
NCT02732730 · results posted 12 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02732730) involved 427 participants in total — 212 in a "Standard Adherence Support" group and 215 in an "Enhanced Adherence Support" group. The trial was measuring how consistently participants took their medication, specifically by testing a biological marker in blood (called TFV-DP) that can indicate whether someone has been taking their tablets regularly. A level of TFV-DP at or above a certain threshold was used as the study's definition of "high adherence" (meaning taking medication consistently as directed). The re...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00622843 · results posted 8 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 229 people across three groups: 131 HIV-positive participants who received a pneumococcal conjugate vaccine (PCV), 73 HIV-positive participants who received a pneumococcal polysaccharide vaccine (PPV), and 25 HIV-negative participants included for comparison. All participants who started the trial completed it. The trial was measuring how the immune systems of HIV-positive people responded to two different types of pneumococcal (pneumonia-related) vaccines, and also tracking any side effects or changes in key health m...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05030766 · results posted 4 June 2025
According to the results reported on ClinicalTrials.gov, this trial looked at two different approaches to help people quit smoking — Mindfulness Training (MT) and Contingency Management (CM) — both combined with Nicotine Replacement Therapy (NRT). The trial ran in two phases. In Phase 1, 49 people were assigned to MT plus NRT and 46 to CM plus NRT. Those who did not quit in Phase 1 could move into Phase 2, where they received the other approach added on top — 12 people continued in an MT plus NRT group with CM added, and 10 in a CM plus NRT group with MT added. The primary outcome the trial m...
-
NCT04801758 · results posted 20 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04801758) enrolled 18 adults living with HIV who were already on antiretroviral therapy (ART). Participants were divided into three groups: 7 received a lower dose of an experimental antibody called VRC01 (10 mg/kg), 5 received a higher dose of VRC01 (30 mg/kg), and 6 received a placebo (an inactive substance). All 18 participants completed the study. The trial was measuring what happened when people temporarily paused their HIV treatment — a period called an "analytical treatment interruption" or ATI — including how long...
-
NCT04994444 · results posted 6 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04994444) involved 49 people in total — 23 in a "preloading" group (where nicotine replacement therapy, or NRT, was started before a quit attempt) and 26 in a "standard treatment" group. The trial was measuring how well people stuck to using nicotine patches over an 8-week period, and also looked at how many people reported not smoking at all in the 7 days before a follow-up check. Not everyone finished the trial — 4 people in the preloading group and 6 in the standard treatment group did not complete it. The reported dat...
-
NCT03157167 · results posted 5 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 people in total across three groups, each receiving a different dose of a radioactive imaging agent called Tc99m-Tilmanocept. The participants all had HIV and had been diagnosed with Kaposi's sarcoma (KS), a type of cancer affecting the skin and other tissues. The trial was testing whether the imaging agent could be given safely at increasing doses, and whether it could show up on scans in KS-affected areas of the body. The three groups received either 100 micrograms with 5 millicuries of radioactivity, 100 microgr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05482360 · results posted 26 February 2025
According to the results reported on ClinicalTrials.gov, this trial looked at three different support packages designed to help healthcare workers offer HIV prevention medication (known as PrEP) to pregnant and postnatal women at clinics in Kenya. Each package was compared against a control group receiving usual care. Across the baseline and intervention periods, roughly 400 or more women participated in each of the six groups, with all participants completing both phases of the study. The trial measured several things: how many women were screened for PrEP, how completely healthcare workers c...
-
NCT03386578 · results posted 19 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03386578) involved pregnant women living with HIV and their infants, and was studying a medication called tenofovir (part of HIV treatment) taken during pregnancy and after birth. The trial had two main parts. The first part — the pharmacokinetics (PK) component, which looks at how a drug moves through the body — enrolled 20 mothers in each of two groups (40 mothers total), along with their infants. The second, larger part compared women who took pre-exposure prophylaxis (PrEP, a medicine to help prevent HIV) with those wh...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05549726 · results posted 24 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05549726) enrolled 984 participants in total — 487 in the "Dynamic Choice Prevention" group (which included access to a long-acting injectable option called cabotegravir, or CAB-LA) and 497 in the "Standard of Care" group. The trial was measuring how much of the time participants were covered by biomedical HIV prevention — meaning they were actively using a prescribed prevention method, such as daily prevention pills (PrEP) or post-exposure pills (PEP) — and whether new HIV infections occurred during the study period. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03367754 · results posted 17 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03367754) enrolled a total of 7 participants — 6 in the pembrolizumab (drug) group and 1 in the placebo group. All 7 participants completed the study with none dropping out. The trial was measuring how often participants experienced certain unwanted health events: specifically, moderate immune-related reactions (known as "grade 2 or higher autoimmune events") that needed steroid treatment, or more serious side effects (grade 3 or higher) that may have been linked to the treatment. Grades refer to a standard scale used to d...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04212091 · results posted 13 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04212091) enrolled a total of 33 participants, split across six groups all receiving a vaccine. The groups ranged in size from 3 to 10 people. The trial was measuring short-term reactions at the injection site (such as pain, tenderness, redness, and swelling), whole-body reactions after vaccination (such as fatigue, headache, nausea, muscle aches, chills, and joint pain), and routine blood test results (including liver-related markers, kidney function, and haemoglobin levels). Most participants completed the study — 30 out...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 207 reported results for HIV and AIDS
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, HIV and AIDS currently attracts a very large amount of public research investment from the United States government. That funding has remained broadly steady from one year to the next, which suggests the field is being maintained as a sustained research priority rather than experiencing sharp rises or falls. For patients, this level of consistent investment signals t...
See the full HIV and AIDS page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.